Huntington disease (HD) is caused by an expanded CAG repeat that sits near the beginning of the gene HD and is translated into a stretch of polyglutamine (polyQ) residues in the corresponding protein, huntingtin. Whereas huntingtin can tolerate a wide variation in the length of this polyQ tract, expansion across a tight threshold causes the late-onset neurological disorder. In vitro experiments have shown that N-terminal huntingtin fragments containing mutant polyQ stretches aggregate to form amyloid fibrils, and the kinetics of aggregation increase dramatically as the polyQ tracts expand across the 'pathogenic' threshold 1 . Both nuclear and extranuclear polyQ aggregates have been observed in the brains of people 2, 3 who, when alive, had HD, and in the brains of mouse models 4, 5 . Of potential significance is the finding that aggregates in autopsied brains are predominantly found in the cytoplasm of the neuron (the neuropil).
Uniting these observations is a study by He Li and colleagues 6 on page 385 that, through use of a mouse model of HD, proposes a mechanism of neuronal dysfunction mediated through interactions occurring outside of the nucleus. The transgenic mouse model, generated by introducing a mutant polyQ tract into one of the mouse HD genes 7 (Hdh), fails to develop motor abnormalities within its lifetime. The changes described are therefore likely to represent the presymptomatic pathology of HD. Indeed, an initial report 7 failed to find evidence of a neuropathology. In the present study, Li et al. have dug deeper, seeking-and finding-evidence of huntingtin aggregation using anti-huntingtin antibodies that are especially sensitive to the aggregated form of the protein 3, 4 . Aggregated huntingtin was detected only in medium spiny striatal neurons, neurons that are most susceptible to degeneration in HD. It was first detected in the cell nucleus and later, in neuronal processes including the synaptic terminals. Whereas this localization is significant, the absence of aggregates from the cerebral cortex may represent a difference between mouse and human; evidence 2, 3 indicates that aggregates first form in the cortex of presymptomatic brains of people with HD. Several lines of evidence [1] [2] [3] 5 indicate that the release of an Nterminal huntingtin fragment probably occurs before the initiation of the aggregation pathway. Until now, such a fragment has not been identified in a mouse model of HD that expresses the full-length protein. Li et al. 6 provide the 'missing link' , with the detection of an N-terminal huntingtin fragment in the nuclear fraction of the striatum by western blot. Notably, the size of this fragment is consistent with that observed in nuclear fractions derived from the brains of juvenile patients 2 and in a mouse model 5 engineered to express a larger portion of huntingtin than the processed fragment. As suggested by the authors, the restricted pattern of aggregate accumulation observed in this model may indicate that huntingtin is processed in a cell-specific manner.
Exploring the neuropil
It has been proposed that the nuclear location of a mutant polyQ protein is essential to its toxicity. The models 8, 9 upon which this proposal is based, however, do not involve the formation of extranuclear aggregates. Whereas there is considerable support for the hypothesis that toxicity is mediated by nuclear events 10 , this does not rule out a parallel extranuclear involvement. Indeed, there is mounting evidence that huntingtin is involved in endocytosis and vesicle trafficking 11 , and it is conceivHunting in the calm before the storm Glutamate galore. The 'green' neuron (a) represents a neuron with normal huntingtin, from which glutamate is secreted by the fusion of synaptic vesicles with the plasma membrane. The red colour of the neuron (b) with mutant N-terminal huntingtin indicates that glutamate has accumulated in the cytoplasm and, as demonstrated by Li et al. 6 , disrupts glutamate uptake into secretory vesicles. Accumulated glutamate is removed from the cell by an unknown mechanism, perhaps through the reversal of glutamate transporters in the cell soma and dendrites.
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There is an overriding mandate to advance the design of gene-transfer vectors. Approaches must be developed to improve levels of efficiency and specificity. To wit: a general evaluation of gene therapy delivered to the United States National Institutes of Health in 1995 (ref. 1) concluded that the development of vectors of improved specificity (also known as tropism) was the first priority. This remains the case today, and a paper 2 presented by Nay Wei Soong and colleagues on page 436 of this issue is a step towards this goal.
Recent events, both tragic and triumphant, highlight the position of vector design as the keystone of the field of gene therapy. In the first regard, the death of Jesse Gelsinger, a young man being treated by gene therapy for an enzyme deficiency, has been attributed to vectorinduced toxicities. Dose-related vector effects may be best addressed by strategies that reduce vector burden, and steps to increase vector specificity represent the most logical means to this end. Not to put too fine a point on it, circumventing the most dire consequences of genetic interventions may be realized through improving vector specificity.
On a more salutary note, the first clear, incontrovertible evidence 3,4 of positive clinical effect has recently emerged from genetherapy trials. Specifically, the results of able that mutant huntingtin exerts a dominant detrimental effect on these processes. Li et al. 6 provide in vitro evidence that the function of synaptic vesicles is impaired. They demonstrate that N-terminal huntingtin fused to glutathione-S-transferase (GST) inhibits glutamate uptake into purified synaptic vesicles, and that it does so with a vigour that correlates with repeat length. The authors suggest that this behaviour is consistent with the extant hypothesis that HD is associated with glutamate excitotoxicity. This may well be the case, but the implications of this observation go beyond the idea of excitotoxicity.
If the presynaptic vesicles are less efficient at glutamate uptake, glutamate levels would increase within the medium spiny projection neurons. This intracellular glutamate must be released into the synaptic cleft so as to exert a biological effect on responsive cells. In the absence of appropriately functioning synaptic vesicles, it is conceivable that this intracellular pool of glutamate may, upon appropriate stimulation, induce the reversal of glutamate transporter activity in these neurons, resulting in the release of glutamate into the extracellular space. Only low levels of glutamate transporter have been detected in neuronal axons 12 . If one assumes that there are no new glutamate transporters to be discovered, it may be that high intracellular glutamate levels in medium spiny neurons reverse the activity of transporters known to be localized at relatively higher levels in the cell bodies and dendrites 12 . If so, the involvement of dendrites in this process would indicate a defect in post-synaptic responsiveness and function in medium spiny neurons rather than a pre-synaptic effect.
Dendritic dysfunction?
A post-synaptic defect in HD is consistent with various hypotheses concerning the aetiology of HD. In particular, it is clear that there is an abundance of neuronal signalling mechanisms in dendrites that can be modulated by pre-synaptic input. Dendritic protein synthesis can also be modulated by pre-synaptic input 13 . And so it is reasonable to hypothesize that any glutamate extruded into the extracellular space through the reversal of dendritic glutamate transporter activity may act directly on the post-synaptic dendrite to alter dendritic functioning by modulating second messenger systems or local protein synthesis.
Certainly, gradual increases in extracellular glutamate with subsequent effects on dendritic signalling could influence neuronal functioning and, in the long term, post-and pre-synaptic terminal viability (as would be expected of a slow neurodegenerative process). Elevated levels of synaptic glutamate may further alter the ability of the post-synaptic dendrite to respond to the input of other modulators (for example, the inhibitory γ-amino-butyric acid) by 'competing' for the activation of particular second messenger systems (see figure) .
Another notable feature of the current study 6 is the demonstration that huntingtin interacts with synaptic vesicles in a lengthdependent manner, indicating proteins on the synaptic vesicle that mediate this interaction. The identity of these proteins should provide insight into the mechanism by which glutamate is excluded from vesicles that bind mutant huntingtin. The model presented by Li et al. is one of several 7, 14, 15 created by introducing a pathogenic polyQ tract into Hdh. The generation of knock-in mice by this approach that model the full range of neuropathology and aspects of neurological deficit is apparently difficult; it is not clear whether the creation of such a model is possible. Nonethless, it seems that a careful exploration of the 'calm' , as represented by the presymptomatic state, may provide clues to avoiding the 'storm' .
